SCHEMBL24155321

SCHEMBL24155321

CCC1CCCc2c1n(Cc1cccc(C(N)=O)c1)c1c(C(=O)O)cccc21

nearest known ligand 0.66

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ FABP4 P15090 10/20 0.66
▸ TBXA2R P21731 9/20 0.51
▸ PTGDR Q13258 9/20 0.51
▸ FABP3 P05413 2/20 0.50
▸ PDE2A O00408 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30573130 1.00 FABP4 (0.66) FABP4TBXA2RPTGDRFABP3PDE2A
SCHEMBL30317268 0.94 FABP4 (0.63) FABP4TBXA2RPTGDRFABP3
SCHEMBL28983470 0.94 FABP4 (0.57) FABP4TBXA2RPTGDRFABP3PDE2A
SCHEMBL30317536 0.94 FABP4 (0.57) FABP4TBXA2RPTGDRFABP3PDE2A
SCHEMBL28983479 0.91 FABP4 (0.62) FABP4TBXA2RPTGDRFABP3
SCHEMBL25935932 0.90 FABP4 (0.54) FABP4TBXA2RPTGDRPDE2A
SCHEMBL30317431 0.89 FABP4 (0.64) FABP4TBXA2RPTGDRFABP3
SCHEMBL26247007 0.88 TBXA2R (0.55) FABP4TBXA2RPTGDRPDE2A
SCHEMBL30317315 0.87 FABP4 (0.61) FABP4TBXA2RPTGDRFABP3
SCHEMBL28983430 0.86 FABP4 (0.67) FABP4FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12138243-B2 Antiviral use of FABP4 modulating compounds CRESCENTA BIOSCIENCES (US) 2024-11-12 — — US claimed
US-12084419-B2 Cell metabolism modulating compounds and uses thereof CRESCENTA BIOSCIENCES (US) 2024-09-10 — — US claimed
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE CRESCENTA BIOSCIENCES (US) 2023-10-19 — — US claimed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 — — US claimed
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-03 — — US claimed
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF CRESCENTA BIOSCIENCES (US) 2022-01-06 — — US claimed
US-12138243-B2 Antiviral use of FABP4 modulating compounds CRESCENTA BIOSCIENCES (US) 2024-11-12 — — US disclosed
US-12084419-B2 Cell metabolism modulating compounds and uses thereof CRESCENTA BIOSCIENCES (US) 2024-09-10 — — US disclosed
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE CRESCENTA BIOSCIENCES (US) 2023-10-19 — — US disclosed
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE CRESCENTA BIOSCIENCES (US) 2023-10-19 — — US disclosed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 — — US disclosed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 — — US disclosed
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-03 — — US disclosed
WO-2022010951-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2022-01-13 — — WO disclosed
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF CRESCENTA BIOSCIENCES (US) 2022-01-06 — — US disclosed
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF CRESCENTA BIOSCIENCES (US) 2022-01-06 — — US disclosed
WO-2021263246-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF CRESCENTA BIOSCIENCES (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FABP4, FABP1, FABP3 FABP4 1/4885TBXA2R 940/4885PTGDR 1076/4885
US-12084419-B2 Cell metabolism modulating compounds and uses thereof FABP4, FABP1, FABP3 FABP4 1/4885TBXA2R 895/4885PTGDR 908/4885
US-20230241025-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 FABP4 2/4885TBXA2R 1741/4885PTGDR 2900/4885
US-12138243-B2 Antiviral use of FABP4 modulating compounds FABP1, FABP5, FABP4 FABP4 3/4885TBXA2R 1752/4885PTGDR 3135/4885
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE FABP4, FABP1, FABP3 FABP4 1/4885TBXA2R 590/4885PTGDR 770/4885
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 FABP4 2/4885TBXA2R 1424/4885PTGDR 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback